BALCHEM (BCPC)

• Balchem reported record Q4 2025 consolidated sales of $264 million, an increase of 9.8% year-over-year, and record full-year 2025 sales of $1.037 billion, marking the first time the company surpassed the $1 billion mark.
• The company achieved record Q4 Adjusted EBITDA of $68 million (up 8.1%) and record full-year Adjusted EBITDA of $275 million (up 9.8%), representing its 26th consecutive quarter of year-over-year Adjusted EBITDA growth.
• Balchem generated record free cash flow of $174 million for 2025, reducing its net debt leverage ratio to 0.3 times, and increased its annual dividend by 10% to $0.96 per share, marking the 17th consecutive year of double-digit dividend growth.
• All three reporting segments contributed to solid year-over-year sales and earnings growth in Q4 2025, with over half of the company's 2025 sales growth originating from international markets.
• Management expressed a positive outlook for 2026, anticipating continued top and bottom-line growth, supported by ongoing strategic initiatives and investments.

• Balchem reported strong financial performance in Q4 2025, with sales increasing 9.8% to $263.6 million and Adjusted EPS growing 15.9% to $1.31 per share.
• For the full year 2025, the company achieved $1.037 billion in sales, an 8.8% increase from FY 2024, and Adjusted EBITDA grew 9.8% to $274.9 million.
• The company announced a 10% increase in its annual dividend, raising it from $0.87 to $0.96 per share, marking the seventeenth consecutive year of double-digit increases.
• All three business segments—Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products—contributed to solid growth on both the top and bottom lines in Q4 2025.

• Balchem reported record consolidated sales of $1.037 billion for the full year 2025, an 8.8% increase over the prior year, and record adjusted EBITDA of $275 million, up 9.8%.
• For Q4 2025, consolidated sales were $264 million, up 9.8%, and adjusted diluted EPS was $1.31, an increase of 15.9% from the prior year.
• The company achieved its 26th consecutive quarter of year-over-year Adjusted EBITDA growth and generated record free cash flow of $174 million for 2025.
• Balchem increased its annual dividend by 10% to $0.96 per share, marking the 17th consecutive year of double-digit growth, and repurchased approximately 685,000 shares at an average cost of $158 per share.
• Over half of the company's sales growth in 2025 came from international markets, and management expects continued top and bottom-line growth for 2026.

• Balchem achieved record financial results for Q4 and full-year 2025, with full-year sales of $1.037 billion, an 8.8% increase year-over-year, and Q4 consolidated revenues of $264 million, up 9.8%. This marked the 26th consecutive quarter of year-over-year Adjusted EBITDA growth.
• The company returned capital to shareholders by repurchasing approximately 685,000 shares at an average cost of $158 per share and increasing its annual dividend by 10% to $0.96 per share, representing the 17th consecutive year of double-digit dividend growth.
• All three reporting segments contributed to growth, with healthy demand across end markets and more than half of 2025 sales growth coming from international markets. The Animal Nutrition and Health segment saw modest improvement in European market conditions for its feed-grade choline business due to anti-dumping duties on Chinese choline.

• Balchem Corporation reported record full year 2025 net sales of $1.037 billion, record adjusted EBITDA of $274.9 million, and record free cash flow of $173.6 million.
• For the fourth quarter of 2025, net sales were $263.6 million, net earnings were $39.2 million, and adjusted EBITDA was $67.9 million.
• GAAP earnings per share for Q4 2025 were $1.21 and $4.75 for the full year 2025, while adjusted earnings per share were $1.31 for Q4 2025 and $5.15 for the full year 2025.
• The company increased its dividend by a double-digit percentage and repurchased $107.636 million of common stock during the full year 2025.

• Balchem Corporation achieved record full-year 2025 net sales of $1.037 billion, an 8.8% increase compared to the prior year, with record GAAP net earnings of $154.8 million and adjusted earnings per share of $5.15.
• For the fourth quarter of 2025, the company reported net sales of $263.6 million, a 9.8% increase from the prior year quarter, and GAAP net earnings of $39.2 million, resulting in GAAP earnings per share of $1.21.
• The company also delivered record full-year 2025 adjusted EBITDA of $274.9 million and record free cash flow of $173.6 million.
• All three reporting segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—demonstrated sales and earnings from operations growth in the fourth quarter of 2025.

Balchem Corporation reported strong financial performance for Q3 2025, continuing its double-digit sales and earnings growth. The company also demonstrated strong cash flows supporting a healthy balance sheet, with all three business segments delivering solid growth. Growth is further strengthened by "better for you" food and nutrition market trends, benefiting Balchem's portfolio of specialty nutrients and functional solutions. Additionally, Balchem has surpassed its 2030 GHG emissions reduction goal, reducing Scope 1 and 2 emissions by 32%.

• Balchem reported record quarterly consolidated sales of $268 million, an 11.5% increase year-over-year, marking its 25th consecutive quarter of year-over-year adjusted EBITDA growth.
• The company achieved record quarterly adjusted EBITDA of $71 million, up 11%, and record adjusted diluted EPS of $1.35, an increase of 19.5% compared to the prior year.
• Human Nutrition and Health segment sales grew 14.3% to $174 million, and the Specialty Products segment grew 7.5%, with Plant Nutrition growing 13%.
• Balchem is investing in a new microencapsulation plant with twice the capacity, expected to be completed and producing by early 2027, to support the 26% growth in its encapsulates business.
• The company's net debt decreased to $89 million, resulting in a leverage ratio of 0.3, and maintains a positive outlook for the remainder of the year.

• Balchem reported record Q3 2025 consolidated revenue of $268 million, an 11.5% increase year-over-year, marking the 25th consecutive quarter of year-over-year adjusted EBITDA growth.
• The company achieved record adjusted EBITDA of $71 million (up 11% year-over-year) and record adjusted diluted EPS of $1.35 (up 19.5% year-over-year).
• All three segments contributed to growth, with the Human Nutrition and Health segment's sales increasing 14.3% to $174 million.
• Construction of a new microencapsulation manufacturing facility in Orange County is expected to be completed in early 2027 and operational by mid-2027, doubling capacity for this high-growth product line.
• The European Union's preliminary anti-dumping duties on China-origin choline chloride are anticipated to receive final approval by the end of 2025, with a five-year term.

• Balchem Corporation reported record net sales of $267.6 million for the third quarter of 2025, an 11.5% increase compared to the prior year quarter.
• The company achieved GAAP net earnings of $40.3 million, up 19.1%, and record adjusted EBITDA of $71.4 million, up 11.0% from the prior year quarter.
• GAAP earnings per share were $1.24 and adjusted earnings per share were $1.35 for Q3 2025, compared to $1.03 and $1.13 respectively in the prior year quarter.
• All three reporting segments, Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products, experienced sales and earnings growth. Balchem is also moving forward with a new microencapsulation manufacturing facility in Orange County, NY, which will more than double capacity , and made net repayments of $36.0 million on its revolving debt, bringing net debt to $88.9 million with a 0.3 times leverage ratio.